Top

Open Access 25-04-2024 | Chronic Obstructive Lung Disease | Review

Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review

Authors: Dave Singh, MeiLan K. Han, Nathaniel M. Hawkins, John R. Hurst, Janwillem W. H. Kocks, Neil Skolnik, Daiana Stolz, Jad El Khoury, Chris P. Gale

Published in: Advances in Therapy

Abstract

Chronic obstructive pulmonary disease (COPD) constitutes a major global health burden and is the third leading cause of death worldwide. A high proportion of patients with COPD have cardiovascular disease, but there is also evidence that COPD is a risk factor for adverse outcomes in cardiovascular disease. Patients with COPD frequently die of respiratory and cardiovascular causes, yet the identification and management of cardiopulmonary risk remain suboptimal owing to limited awareness and clinical intervention. Acute exacerbations punctuate the progression of COPD in many patients, reducing lung function and increasing the risk of subsequent exacerbations and cardiovascular events that may lead to early death. This narrative review defines and summarises the principles of COPD-associated cardiopulmonary risk, and examines respiratory interventions currently available to modify this risk, as well as providing expert opinion on future approaches to addressing cardiopulmonary risk.

Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5: 020415. https://doi.org/10.7189/jogh.05.020415.CrossRefPubMedPubMedCentral

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease report 2024. https://goldcopd.org/2024-gold-report/. Accessed 5 Jan 2024.

World Health Organization. Chronic obstructive pulmonary disease (COPD) 2023. https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd). Accessed 6 Feb 2024.

Mathers C. Projections of global deaths from 2016 to 2060 2022. https://colinmathers.com/2022/05/10/projections-of-global-deaths-from-2016-to-2060/. Accessed 9 Nov 2023.

Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3:631–9. https://doi.org/10.1016/S2213-2600(15)00241-6.CrossRefPubMed

Amegadzie JE, Sadatsafavi M. A long overdue recognition: COPD as a distinct predictor of cardiovascular disease risk. Eur Respir J. 2023;62:2301167. https://doi.org/10.1183/13993003.01167-2023.CrossRefPubMed

Müllerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144:1163–78. https://doi.org/10.1378/chest.12-2847.CrossRefPubMed

Forfia PR, Vaidya A, Wiegers SE. Pulmonary heart disease: the heart-lung interaction and its impact on patient phenotypes. Pulm Circ. 2013;3:5–19. https://doi.org/10.4103/2045-8932.109910.CrossRefPubMedPubMedCentral

Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. 2013;1:73–83. https://doi.org/10.1016/S2213-2600(12)70060-7.CrossRefPubMed

10.

Maclagan LC, Croxford R, Chu A, Sin DD, Udell JA, Lee DS, et al. Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort. Eur Respir J. 2023;62:2202364. https://doi.org/10.1183/13993003.02364-2022.CrossRefPubMed

11.

Fabbri LM, Celli BR, Agustí A, Criner GJ, Dransfield MT, Divo M, et al. COPD and multimorbidity: recognising and addressing a syndemic occurrence. Lancet Respir Med. 2023;11:1020–34. https://doi.org/10.1016/S2213-2600(23)00261-8.CrossRefPubMed

12.

Hurst JR, Skolnik N, Hansen GJ, Anzueto A, Donaldson GC, Dransfield MT, et al. Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life. Eur J Intern Med. 2020;73:1–6. https://doi.org/10.1016/j.ejim.2019.12.014.CrossRefPubMed

13.

Hughes R, Rapsomaniki E, Janson C, Keen C, Make BJ, Burgel P-R, et al. Frequent productive cough: symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study. Respir Med. 2022;200: 106921. https://doi.org/10.1016/j.rmed.2022.106921.CrossRefPubMed

14.

Kunisaki KM, Dransfield MT, Anderson JA, Brook RD, Calverley PM, Celli BR, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018;198:51–7. https://doi.org/10.1164/rccm.201711-2239OC.CrossRefPubMedPubMedCentral

15.

Rothnie KJ, Müllerová H, Smeeth L, Quint JK. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198:464–71. https://doi.org/10.1164/rccm.201710-2029OC.CrossRefPubMedPubMedCentral

16.

Mannino DM, Doherty DE, Sonia BA. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med. 2006;100:115–22. https://doi.org/10.1016/j.rmed.2005.03.035.CrossRefPubMed

17.

Foos V, Mcewan P, Holmgren U, Marshall J, Müllerová H, Nigris ED. Projections of 10-year mortality in patients with COPD in the UK using the CHOPIN policy model. Eur Respir J. 2021;58(Suppl. 65):PA1012. https://doi.org/10.1183/13993003.congress-2021.PA1012. (Abstract).CrossRef

18.

Matarese A, Sardu C, Shu J, Santulli G. Why is chronic obstructive pulmonary disease linked to atrial fibrillation? A systematic overview of the underlying mechanisms. Int J Cardiol. 2019;276:149–51. https://doi.org/10.1016/j.ijcard.2018.10.075.CrossRefPubMed

19.

Chen C-C, Lin C-H, Hao W-R, Chiu C-C, Fang Y-A, Liu J-C, et al. Association between chronic obstructive pulmonary disease and ventricular arrhythmia: a nationwide population-based cohort study. NPJ Prim Care Respir Med. 2021;31:8. https://doi.org/10.1038/s41533-021-00221-3.CrossRefPubMedPubMedCentral

20.

Liu X, Chen Z, Li S, Xu S. Association of chronic obstructive pulmonary disease with arrhythmia risks: a systematic review and meta-analysis. Front Cardiovasc Med. 2021;8: 732349. https://doi.org/10.3389/fcvm.2021.732349.CrossRefPubMedPubMedCentral

21.

Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis. 2009;4:337–49. https://doi.org/10.2147/copd.s6400.CrossRefPubMedPubMedCentral

22.

Krishnan S, Tan WC, Farias R, Aaron SD, Benedetti A, Chapman KR, et al. Impaired spirometry and COPD increase the risk of cardiovascular disease: a Canadian cohort study. Chest. 2023;164:637–49. https://doi.org/10.1016/j.chest.2023.02.045.CrossRefPubMed

23.

Carter P, Lagan J, Fortune C, Bhatt DL, Vestbo J, Niven R, et al. Association of cardiovascular disease with respiratory disease. J Am Coll Cardiol. 2019;73:2166–77. https://doi.org/10.1016/j.jacc.2018.11.063.CrossRefPubMed

24.

Amegadzie JE, Gao Z, Quint JK, Russell R, Hurst JR, Lee TY, et al. QRISK3 underestimates the risk of cardiovascular events in patients with COPD. Thorax. 2023. https://doi.org/10.1136/thorax-2023-220615.CrossRefPubMed

25.

Watz H, Tetzlaff K, Magnussen H, Mueller A, Rodriguez-Roisin R, Wouters EF, et al. Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial. Respir Res. 2018;19:251. https://doi.org/10.1186/s12931-018-0944-3.CrossRefPubMedPubMedCentral

26.

Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67:957–63. https://doi.org/10.1136/thoraxjnl-2011-201518.CrossRefPubMed

27.

Goto T, Shimada YJ, Faridi MK, Camargo CA, Hasegawa K. Incidence of acute cardiovascular event after acute exacerbation of COPD. J Gen Intern Med. 2018;33:1461–8. https://doi.org/10.1007/s11606-018-4518-3.CrossRefPubMedPubMedCentral

28.

Müllerová H, Marshall J, de Nigris E, Varghese P, Pooley N, Embleton N, et al. Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis. Ther Adv Respir Dis. 2022;16:17534666221113648. https://doi.org/10.1177/17534666221113647.CrossRefPubMedPubMedCentral

29.

Nordon C, Rhodes K, Quint JK, Vogelmeier CF, Simons SO, Hawkins NM, et al. EXAcerbations of COPD and their OutcomeS on CardioVascular diseases (EXACOS-CV) Programme: protocol of multicountry observational cohort studies. BMJ Open. 2023;13: e070022. https://doi.org/10.1136/bmjopen-2022-070022.CrossRefPubMedPubMedCentral

30.

Graul EL, Nordon C, Rhodes K, Marshall J, Menon S, Kallis C, et al. Temporal risk of non-fatal cardiovascular events post COPD exacerbation: a population-based study. Am J Respir Crit Care Med. 2023. https://doi.org/10.1164/rccm.202307-1122OC.CrossRef

31.

Hawkins NM, Nordon C, Rhodes K, Talukdar M, McMullen S, Ekwaru P, et al. Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease. Heart. 2024. https://doi.org/10.1136/heartjnl-2023-323487.CrossRefPubMed

32.

Vogelmeier C, Simons S, Garbe E, Sin D, Hawkins N, Manito N, et al. Increased risk of severe cardiovascular events following exacerbations of COPD: a multi-database cohort study. Eur Respir J 2023;62:PA3013 (Abstract).

33.

Swart KMA, Baak BN, Lemmens L, Penning-van Beest FJA, Bengtsson C, Lobier M, et al. Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: results from the EXACOS-CV cohort study using the PHARMO Data Network in the Netherlands. Respir Res. 2023;24:293. https://doi.org/10.1186/s12931-023-02601-4.CrossRefPubMedPubMedCentral

34.

Dransfield MT, Criner GJ, Halpin, Han MK, Hartley B, Kalhan R, et al. Time‐dependent risk of cardiovascular events following an exacerbation in patients with chronic obstructive pulmonary disease: post hoc analysis from the IMPACT trial. J Am Heart Assoc 2022;11:e024350. https://doi.org/10.1161/JAHA.121.024350.

35.

Westerik JA, Metting EI, van Boven JF, Tiersma W, Kocks JW, Schermer TR. Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respir Res. 2017;18:31. https://doi.org/10.1186/s12931-017-0512-2.CrossRefPubMedPubMedCentral

36.

Curkendall SM, deLuise C, Jones JK, Lanes S, Stang MR, Goehring E, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada: cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63–70. https://doi.org/10.1016/j.annepidem.2005.04.008.CrossRefPubMed

37.

Williams MC, Murchison JT, Edwards LD, Agustí A, Bakke P, Calverley PM, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax. 2014;69:718–23. https://doi.org/10.1136/thoraxjnl-2012-203151.CrossRefPubMed

38.

Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–38. https://doi.org/10.1056/NEJMoa0909883.CrossRefPubMed

39.

Sadatsafavi M, McCormack J, Petkau J, Lynd LD, Lee TY, Sin DD. Should the number of acute exacerbations in the previous year be used to guide treatments in COPD? Eur Respir J. 2021;57:2002122. https://doi.org/10.1183/13993003.02122-2020.CrossRefPubMedPubMedCentral

40.

Ho JK, Safari A, Adibi A, Sin DD, Johnson K, Sadatsafavi M, et al. Generalizability of risk stratification algorithms for exacerbations in COPD. Chest. 2023;163:790–8. https://doi.org/10.1016/j.chest.2022.11.041.CrossRefPubMed

41.

Sharma V, Ali I, van der Veer S, Martin G, Ainsworth J, Augustine T. Adoption of clinical risk prediction tools is limited by a lack of integration with electronic health records. BMJ Health Care Inform. 2021;28: e100253. https://doi.org/10.1136/bmjhci-2020-100253.CrossRefPubMedPubMedCentral

42.

Dudina A, Lane S, Butler M, Cooney M-T, Graham I. SURF-COPD: the recording of cardiovascular risk in patients with chronic lung disease. QJM. 2018;111:303–6. https://doi.org/10.1093/qjmed/hcy028.CrossRefPubMed

43.

Müllerová H, Shukla A, Hawkins A, Quint J. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open. 2014;4: e006171. https://doi.org/10.1136/bmjopen-2014-006171.CrossRefPubMedPubMedCentral

44.

Rapsomaniki E, Müllerová H, Hughes R, Marshall J, Papi A, Reddel H, et al. Frequent productive cough associates with an increased risk of cardiopulmonary outcomes in a real-life cohort of patients with COPD (NOVELTY study). Eur Respir J. 2023;62(Suppl. 67):PA1928 (Abstract).

45.

Van Eeden S, Leipsic J, Paul Man SF, Sin DD. The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med. 2012;186:11–6. https://doi.org/10.1164/rccm.201203-0455PP.CrossRefPubMed

46.

Aisanov Z, Khaltaev N. Management of cardiovascular comorbidities in chronic obstructive pulmonary disease patients. J Thorac Dis. 2020;12:2791–802. https://doi.org/10.21037/jtd.2020.03.60.CrossRefPubMedPubMedCentral

47.

Vassaux C, Torre-Bouscoulet L, Zeineldine S, Cortopassi F, Paz-Díaz H, Celli BR, et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. Eur Respir J. 2008;32:1275–82. https://doi.org/10.1183/09031936.00151707.CrossRefPubMed

48.

Kent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with COPD: cause, effects, and disease progression. Int J Chron Obstruct Pulmon Dis. 2011;6:199–208. https://doi.org/10.2147/COPD.S10611.CrossRefPubMedPubMedCentral

49.

Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018;27: 180057. https://doi.org/10.1183/16000617.0057-2018.CrossRefPubMedPubMedCentral

50.

Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–54. https://doi.org/10.1056/NEJMoa0805800.CrossRefPubMed

51.

Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364:1093–103. https://doi.org/10.1056/NEJMoa1008378.CrossRefPubMed

52.

Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD. N Engl J Med. 2016;374:2222–34. https://doi.org/10.1056/NEJMoa1516385.CrossRefPubMed

53.

Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671–80. https://doi.org/10.1056/NEJMoa1713901.CrossRefPubMed

54.

Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383:35–48. https://doi.org/10.1056/NEJMoa1916046.CrossRefPubMed

55.

Halpin DM, Dransfield MT, Han MK, Jones CE, Kilbride S, Lange P, et al. The effect of exacerbation history on outcomes in the IMPACT trial. Eur Respir J. 2020;55:1901921. https://doi.org/10.1183/13993003.01921-2019.CrossRefPubMedPubMedCentral

56.

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196:438–46. https://doi.org/10.1164/rccm.201703-0449OC.CrossRefPubMed

57.

Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6:747–58. https://doi.org/10.1016/S2213-2600(18)30327-8.CrossRefPubMed

58.

Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389:1919–29. https://doi.org/10.1016/S0140-6736(17)30188-5.CrossRefPubMed

59.

Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β₂-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388:963–73. https://doi.org/10.1016/S0140-6736(16)31354-X.CrossRefPubMed

60.

Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391:1076–84. https://doi.org/10.1016/S0140-6736(18)30206-X.CrossRefPubMed

61.

Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post hoc analysis of three randomised trials. Lancet Respir Med. 2018;6:117–26. https://doi.org/10.1016/S2213-2600(18)30006-7.CrossRefPubMed

62.

Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7:745–56. https://doi.org/10.1016/S2213-2600(19)30190-0.CrossRefPubMed

63.

Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M, et al. Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on COPD exacerbations, lung function, symptoms, and quality of life across blood eosinophil ranges: a post hoc analysis of data from ETHOS. Int J Chron Obstruct Pulmon Dis. 2022;17:3061–73. https://doi.org/10.2147/COPD.S374670.CrossRefPubMedPubMedCentral

64.

Strange C, Tkacz J, Schinkel J, Lewing B, Agatep B, Swisher S, et al. Int J Chron Obstruct Pulmon Dis. 2023;18:2245–2256. https://doi.org/10.2147/COPD.S432963CrossRefPubMedPubMedCentral

65.

Ismaila AS, Rothnie KJ, Wood RP, Banks VL, Camidge LJ, Czira A, et al. Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study. Respir Res. 2023;24:229. https://doi.org/10.1186/s12931-023-02523-1.CrossRefPubMedPubMedCentral

66.

Löfdahl C-G, Postma DS, Pride NB, Boe J, Thorén A. Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur Respir J. 2007;29:1115–9. https://doi.org/10.1183/09031936.00128806.CrossRefPubMed

67.

Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann H-C, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018;6:368–78. https://doi.org/10.1016/S2213-2600(18)30054-7.CrossRefPubMed

68.

Kellerer C, Kahnert K, Trudzinski FC, Lutter J, Berschneider K, Speicher T, et al. COPD maintenance medication is linked to left atrial size: results from the COSYCONET cohort. Respir Med. 2021;185: 106461. https://doi.org/10.1016/j.rmed.2021.106461.CrossRefPubMed

69.

Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387:1817–26. https://doi.org/10.1016/S0140-6736(16)30069-1.CrossRefPubMed

70.

Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for COPD: a randomized, double-blind, multi-center, parallel-group study. Am J Respir Crit Care Med. 2020;203:553–64. https://doi.org/10.1164/rccm.202006-2618OC.CrossRef

71.

Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DM, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in COPD patients. Am J Respir Crit Care Med. 2020;201:1508–16. https://doi.org/10.1164/rccm.201911-2207OC.CrossRefPubMedPubMedCentral

72.

Vestbo J, Fabbri L, Papi A, Petruzzelli S, Scuri M, Guasconi A, et al. Inhaled corticosteroid containing combinations and mortality in COPD. Eur Respir J. 2018;52:1801230. https://doi.org/10.1183/13993003.01230-2018.CrossRefPubMed

73.

Yang M, Li Y, Jiang Y, Guo S, He J-Q, Sin DD. Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. Eur Respir J. 2023;61:2200302. https://doi.org/10.1183/13993003.00302-2022.CrossRefPubMed

74.

Regard L, Burgel P-R, Roche N. Inhaled therapy, cardiovascular risk and benefit–risk considerations in COPD: innocent until proven guilty, or vice versa? Eur Respir J. 2023;61:2202135. https://doi.org/10.1183/13993003.02135-2022.CrossRefPubMed

75.

Stolz D, Cazzola M. Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists. In: Martínez-García MÁ, Pépin J-L, Cazzola M, editors. Cardiovascular complications of respiratory disorders. Sheffield: European Respiratory Society; 2020. p. 238–50. https://doi.org/10.1183/2312508X.10028619.CrossRef

76.

Godtfredsen NS, Lam TH, Hansel TT, Leon ME, Gray N, Dresler C, et al. COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J. 2008;32:844–53. https://doi.org/10.1183/09031936.00160007.CrossRefPubMed

77.

Ryrsø CK, Godtfredsen NS, Kofod LM, Lavesen M, Mogensen L, Tobberup R, et al. Lower mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a systematic review and meta-analysis. BMC Pulm Med. 2018;18:154. https://doi.org/10.1186/s12890-018-0718-1.CrossRefPubMedPubMedCentral

78.

Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93:391–8. https://doi.org/10.7326/0003-4819-93-3-391.CrossRef

79.

Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. 1981;317:681–6. https://doi.org/10.1016/S0140-6736(81)91970-X.CrossRef

80.

Murphy PB, Rehal S, Arbane G, Bourke S, Calverley PM, Crook AM, et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA. 2017;317:2177–86. https://doi.org/10.1001/jama.2017.4451.CrossRefPubMedPubMedCentral

81.

Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–89.CrossRefPubMed

82.

Pullen R, Miravitlles M, Sharma A, Singh D, Martinez F, Hurst JR, et al. CONQUEST quality standards: for the collaboration on quality improvement initiative for achieving excellence in standards of COPD care. Int J Chron Obstruct Pulmon Dis. 2021;16:2301–22. https://doi.org/10.2147/COPD.S313498.CrossRefPubMedPubMedCentral

83.

Celi A, Latorre M, Paggiaro P, Pistelli R. Chronic obstructive pulmonary disease: moving from symptom relief to mortality reduction. Ther Adv Chronic Dis. 2021;12:20406223211014028. https://doi.org/10.1177/20406223211014028.CrossRefPubMedCentral

84.

O’Donnell DE, Webb KA, Neder JA. Lung hyperinflation in COPD: applying physiology to clinical practice. COPD Res Pract. 2015;1:4. https://doi.org/10.1186/s40749-015-0008-8.CrossRef

85.

García-Río F. Lung hyperinflation in chronic obstructive pulmonary disease: clinical and therapeutic relevance. BRN Rev. 2020;6:67–86.

86.

Hwang HJ, Lee SM, Seo JB, Lee JS, Kim N, Kim C, et al. Assessment of changes in regional xenon-ventilation, perfusion, and ventilation-perfusion mismatch using dual-energy computed tomography after pharmacological treatment in patients with chronic obstructive pulmonary disease: visual and quantitative analysis. Int J Chron Obstruct Pulmon Dis. 2019;14:2195–203. https://doi.org/10.2147/COPD.S210555.CrossRefPubMedPubMedCentral

87.

Singh D, Wild JM, Saralaya D, Lawson R, Marshall H, Goldin J, et al. Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial. Respir Res. 2022;23:26. https://doi.org/10.1186/s12931-022-01949-3.CrossRefPubMedPubMedCentral

88.

Voskrebenzev A, Kaireit TF, Klimeš F, Pöhler GH, Behrendt L, Biller H, et al. PREFUL MRI depicts dual bronchodilator changes in COPD: a retrospective analysis of a randomized controlled trial. Radiol Cardiothorac Imaging. 2022;4: e210147. https://doi.org/10.1148/ryct.210147.CrossRefPubMedPubMedCentral

89.

Shrikrishna D, Taylor CJ, Stonham C, Gale CP. Exacerbating the burden of cardiovascular disease: how can we address cardiopulmonary risk in individuals with chronic obstructive pulmonary disease? Eur Heart J. 2024;45:247–9. https://doi.org/10.1093/eurheartj/ehad669.CrossRefPubMed

90.

Singh D, Holmes S, Adams C, Bafadhel M, Hurst JR. Overcoming therapeutic inertia to reduce the risk of COPD exacerbations: four action points for healthcare professionals. Int J Chron Obstruct Pulmon Dis. 2021;16:3009–16. https://doi.org/10.2147/COPD.S329316.CrossRefPubMedPubMedCentral

91.

Kocks J, Ferreira AJ, Bakke P, van Schayck OC, Ekroos H, Tzanakis N, et al. Investigating the rationale for COPD maintenance therapy prescription across Europe, findings from a multi-country study. NPJ Prim Care Respir Med. 2023;33:18. https://doi.org/10.1038/s41533-023-00334-x.CrossRefPubMedPubMedCentral

92.

Mannino D, Siddall J, Small M, Haq A, Stiegler M, Bogart M. Treatment patterns for chronic obstructive pulmonary disease (COPD) in the United States: results from an observational cross-sectional physician and patient survey. Int J Chron Obstruct Pulmon Dis. 2022;17:749–61. https://doi.org/10.2147/COPD.S340794.CrossRefPubMedPubMedCentral

93.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease report 2023. https://goldcopd.org/wp-content/uploads/2023/03/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf. Accessed 18 Jan 2024.

94.

Bourbeau J, Bhutani M, Hernandez P, Aaron SD, Beauchesne M-F, Kermelly SB, et al. 2023 Canadian Thoracic Society guideline on pharmacotherapy in patients with stable COPD. Chest. 2023;164:1159–83. https://doi.org/10.1016/j.chest.2023.08.014.CrossRefPubMed

95.

Agusti A, Böhm M, Celli B, Criner GJ, Garcia-Alvarez A, Martinez F, et al. GOLD COPD DOCUMENT 2023: a brief update for practicing cardiologists. Clin Res Cardiol. 2023;2023:1–10. https://doi.org/10.1007/s00392-023-02217-0.CrossRef

Title: Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review
Authors: Dave Singh
MeiLan K. Han
Nathaniel M. Hawkins
John R. Hurst
Janwillem W. H. Kocks
Neil Skolnik
Daiana Stolz
Jad El Khoury
Chris P. Gale
Publication date: 25-04-2024
Publisher: Springer Healthcare
Keyword: Chronic Obstructive Lung Disease
Published in: Advances in Therapy
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-024-02855-4

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage